about
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cellsPotential use of rapamycin in HIV infectionRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceAutophagy in acute leukemias: a double-edged sword with important therapeutic implicationsEmerging targeted therapies for melanoma treatment (review)Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma CancerRegulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylasesPI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancerTargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.Kinases: positive and negative regulators of apoptosis.Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy.The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineActivation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells.Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cellsTargeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.Targeting the leukemic stem cell: the Holy Grail of leukemia therapyA PTEN inhibitor displays preclinical activity against hepatocarcinoma cellsSuppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.Senescence-associated exosome release from human prostate cancer cells.Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Emerging Raf inhibitors.Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.
P50
Q24338523-851BA5D8-3A8E-461D-A170-496F5811A530Q24606795-26BB98A0-CDB4-4337-B0D5-683431E35F51Q24645668-C8B979CF-AF80-4A51-B45B-1059AD55C37FQ26828544-650562B3-4A11-435E-BE7D-380527B23400Q26829997-B57C8053-51BC-4E55-8EBA-FF1470D6A1D3Q28551002-70CB30E0-08FB-4CC9-9B1A-B208845F807DQ30371492-C3FE9A02-F06B-48AB-8945-896BDD61CE61Q33291674-ECB6B8F8-AB0F-4591-BC7B-8864EBB55AE7Q33493174-E285C7DC-69D5-4284-9419-011B42C0DDA8Q33591225-AD94E7B9-7D5F-4A20-8D34-455B193BCB1DQ33823577-645A4FB8-0C16-4DB5-9AF6-A091CA1AA01AQ33952803-CB02A3F8-21D8-4355-B1E1-2BE5245EC8BEQ34000650-BBFAC5AA-91E5-4D98-BD40-F055092CD5D9Q34144498-8100E47B-887B-4906-B4DF-86D18D5A435DQ34184917-6C22A666-5976-4CF9-A46C-812B2071D7BDQ34244242-4F2AFE35-4A0A-417E-9607-E8BCEDC84D2AQ34775779-03FE0506-8FE4-44BA-8983-6BF1416CE72BQ34979356-E169C5B9-ADC5-49BB-8D22-123DEB30FC24Q35020561-EB57BC72-6964-403B-A2B4-7AEE0E6CE8B0Q35166852-34A6A53E-FFB4-4C4A-BA5E-454DF67A763BQ36219718-32887AD3-4A97-459B-9095-640053C3BA4BQ36268324-8A2E87D5-CE51-4640-85DD-45FB1729B55DQ36544778-03717294-4E08-4648-A344-056540E0851CQ36556350-2C83A6EF-E8B8-4C6B-84C8-7FAB19B52098Q36598871-77ECA99E-396C-42AA-BB0C-A25A76C37101Q36738818-94370C1E-C69D-4A9C-939F-E7FAFBE09CD3Q36858555-5C7C0D99-FADC-4B06-A2E4-E8394268DD98Q37001645-7E334F94-095D-4FD8-81D5-AFD5E5EDB40BQ37015029-57518B36-C248-46E0-B37D-FDB55A72F552Q37109225-A1400E60-1AB6-4BF8-A88D-48C2DE4AC911Q37109227-19664D8E-E3D3-435D-B315-43E2B8B76705Q37138122-24AE8DC6-DDD6-4F1A-B92D-7D82199E86E0Q37272565-147A37F0-7FDB-45B6-AB1C-9ACA864192B4Q37324522-14AFB5E5-847D-4EDD-8665-50D209C37412Q37331720-A8F86E23-814B-4572-B606-4AAB2F06797BQ37331742-DF362A53-157B-429D-B26B-6ACB0B9B28EAQ37352797-C98E1CC1-BE29-4551-B06F-05F29F3E33CFQ37460101-BF2104AA-5D12-42A5-9ED0-82A257103845Q37588717-8B11FF16-B3CB-4DBF-B793-31D2F9BB3F44Q37588790-74B79361-8D3E-44BB-80E2-CDDA2CA4DFC9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
James A. McCubrey
@ast
James A. McCubrey
@en
James A. McCubrey
@es
James A. McCubrey
@nl
James A. McCubrey
@sl
type
label
James A. McCubrey
@ast
James A. McCubrey
@en
James A. McCubrey
@es
James A. McCubrey
@nl
James A. McCubrey
@sl
altLabel
James A. McCubrey
@en
James Andrew McCubrey
@en
prefLabel
James A. McCubrey
@ast
James A. McCubrey
@en
James A. McCubrey
@es
James A. McCubrey
@nl
James A. McCubrey
@sl
P106
P1153
7004993472
P21
P31
P496
0000-0001-6027-3156